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■ BACKGROUND: Inflammatory and vascular markers have
proved to be predictors of outcome in myocardial
infarction and heart failure. We evaluated several circu-
lating markers of cardiac stress, inflammation, and
endothelial function to investigate their ability to pre-
dict short-term functional recovery and long-term clini-
cal outcome in heart surgery patients undergoing inpa-
tient rehabilitation.
■ METHODS: This prospective, multicenter study enrolled
223 patients after heart surgery, included in a 3-week
program of standardized and supervised physical train-
ing. The association between biomarkers (pentraxin-3
[PTX3], brain natriuretic peptide, high-sensitivity car-
diac troponin-T [hs-cTnT] and C-reactive protein
[hsCRP], creatine kinase, myoglobin, and urinary albu-
min excretion [UACR]) and exercise capacity (6-minute
walk test, 6MWT) or 1-year incidence of major adverse
cardiovascular events (MACE) was tested in models that
included biohumoral markers, and clinical and instru-
mental variables.
■ RESULTS: The patients (69.5% men, mean age of 67  11
years) were enrolled after valvular surgery (52.7%)
and 58.6% after coronary artery bypass grafting
(CABG). Exercise capacity improved during rehabilita-
tion (6MWT distance from 279  95 to 386  91 m;
P  .0001); concentrations of most biomarkers
decreased (hsCRP: 79% [P  .0001]; hs-cTnT: 57% 
[P  .0001]; UACR: 36% [P  .05]). Among the test-
ed markers, PTX3 showed the closest association with
6MWT distance (P  .01) and was the only predictor
of MACE, also in the subgroup of CABG patients (OR
[95% CI]  1.14 [1.03-1.27]; P  .015).
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Venous blood and spot urine samples were col-
lected at the beginning and end of the 3-week reha-
bilitation period. The rehabilitation program consist-
ed of standardized and supervised physical training
with incremental exercise (up to 30 minutes of
cycling 5 times a week at 70% maximal heart rate) in
accordance with the international guidelines.13-15 The
program was continued throughout the period of
hospitalization depending on patient clinical condi-
tion, and for a further 6 weeks after discharge. At the
end of the rehabilitation period, patients underwent a
second clinical cardiac examination and repeated the
instrumental tests administered at the time of enrol-
ment; they also repeated the 6MWT.
Measurement of Circulating Biomarkers
Upon study entry, routine blood chemistry tests were
integrated with measurements of various circulating
biomarkers. The protocol for the collection and pro-
cessing biological samples was predefined and stan-
dardized. All tests were repeated at the end of the 3-
week rehabilitation program. The blood was
processed to obtain plasma and serum samples that
were immediately frozen and stored at 70°C until
analysis. The determinations were made in a single run
by central laboratory personnel blinded to the experi-
mental groups and included brain natriuretic peptide
(BNP, MEIA AxSYM-Abbott, Abbott Park, IL), high-sen-
sitivity cardiac troponin-T (hs-cTnT, Elecsys, Roche
Diagnostics, Mannheim, Germany)16, pentraxin-3
(PTX3, ELISA based on in-house reagents17), high-sen-
sitive C-reactive protein (hsCRP, turbidimetric method,
Beckman Coulter DxC800, Brea, CA), myoglobin
(MEIA AxSYM-Abbott), creatine kinase (CK, Rosalki
enzymatic method), creatine kinase isoenzyme MB
(CK-MB, MEIA Axsym-Abbott, Abbott Park, IL).
Urinary albumin excretion was measured using a
radioimmunoassay (coated tubes, Immunotech,
Marseille, France), indexed to creatinine, and
expressed as the urinary albumin-to-creatinine ratio
(UACR, mg/g of creatinine).3
Followup
Patients were followed for 12 months after hospital
discharge by means of clinic visits or telephone con-
tacts to record any major clinical events. Major
adverse cardiovascular events (MACE) were defined
as the composite endpoint of death or unplanned
hospital admission due to cardiac causes.
A number of hemodynamic, remodeling, inflammatory,
and vascular biomarkers, including brain natriuretic
peptide (BNP), cardiac troponins, C-reactive protein
(CRP), and microalbuminuria, have proved to be pre-
dictive of outcomes in patients with myocardial
infarction (MI) and heart failure,1-4 but there is still a
lack of reliable outcome predictors in cardiac reha-
bilitation. Pentraxin-3 (PTX-3) has emerged as a new
candidate marker of inflammation, infection, and car-
diovascular disease.5 The aim of this study was to
investigate the predictive capacity of some hemody-
namic, remodeling, inflammatory, and vascular bio-
markers (in addition to the more frequently used clin-
ical and laboratory variables) in relation to short-term
functional recovery and long-term clinical outcomes
in heart surgery patients attending inpatient rehabili-
tation centers.
METHODS
This multicenter study enrolled 223 patients undergo-
ing rehabilitation after elective coronary artery bypass
graft (CABG) and/or valve replacement or repair. The
protocol was approved by the local ethics commit-
tees, and all patients gave their written informed con-
sent. The patients were consecutively recruited at 4
cardiology rehabilitation centers of the Don Gnocchi
Foundation located in Northern, Central, and
Southern Italy. The exclusion criteria were con-
traindications to physical training and chronic hema-
tological and immunological diseases.
Study Design
Upon study entry, a mean 9  5 (SD) days after car-
diac surgery, the clinical history of patients was
recorded and each underwent a complete cardiac
assessment, including chest radiography, electrocar-
diography, transthoracic Doppler echocardiography,
and a 6-minute walk test (6MWT). The 6MWT,6,7
which provides postsurgical functional information8
that correlates with peak oxygen uptake9 and clinical
variables such as gender, age, weight, and height,10-12
was used as a surrogate marker of short-term func-
tional recovery. It was carried out on the basis of a
standardized protocol under the supervision of trained
professionals and utilizing monitoring of blood pres-
sure, heart rate and oxygen saturation.
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■ CONCLUSION: PTX3, a marker of vascular inflammation
and cardiovascular damage, is a predictor of short-term
functional recovery and 1-year MACE in patients under-
going rehabilitation after cardiac surgery, regardless of
clinical and instrumental parameters.
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than 13.5 ng/L, 63.7% hsCRP levels of more than 
3 mg/L, 79.3% UACR levels of more than 3 mg/g, and
20.4% high myoglobin levels (72 µg/L for men, 
51 µg/L for women). The 179 patients (82.1%) who
underwent cardiac surgery with a cardiopulmonary
bypass (on-pump) had high baseline levels of hs-
cTnT (70 [33-155] vs 28 [16-75] pg/mL, P  .0003 vs
off-pump surgery) and hsCRP (4.0 [2.5-6.4] vs 2.6 [1.3-
3.9] mg/L, P  .007) but not of the other biomarkers.
Figure 1 shows the differences in biomarker concen-
trations between the start and end of the period of
rehabilitation, by which time all except CK-MB had
decreased significantly, with the greatest reductions
in hsCRP (79%, P  .0001), hs-cTnT (57%, P  .0001),
and UACR (36%, P  .05).
Exercise capacity improved significantly during
rehabilitation as reflected by the increase in the dis-
tance of the 6MWT from 279  95 m at the start of
the program to 386  91 m at the end (P  .0001).
We next identified the clinical variables associated
with the results of the 6MWT at the end of the reha-
bilitation period. Univariate analysis showed that an
advanced age, a reduced LV ejection fraction and
reduced renal function (eGFR) were all independent-
ly associated with a shorter distance (Table 2), as
were higher admission levels of the biomarkers PTX3
(P  .003), BNP (P  .04), and myoglobin (P  .05)
(Table 3). Only PTX3 remained a statistically signifi-
cant predictor in a multivariable model including the
three markers (P  .01). PTX3 was also marginally
associated with the outcome of rehabilitation in a
final model that included the significant clinical pre-
dictors and biomarkers (P  0.07, Table 4).
Twenty-four patients (11.9%) experienced a MACE
after a median followup of 360 (298-381) days: 20 under-
went an unplanned hospital admission due to cardiac
causes, and the remaining 4 died (1.8%). Upon admis-
sion, these patients were older (72  9 vs 67  11 years)
and had a lower LVEF (49.5  10.5 vs 54.2  10.1%) and
eGFR (63  27 vs 75  23 mL/min/1.73 m2) than the
event-free patients. They also had higher baseline plasma
concentrations of myoglobin (median [Q1-Q3]  45 [31-
61] vs 29 [24-41] µg/L) and PTX3 (median [Q1-Q3]  12.4
[10.2-18.9] vs 9.4 [6.6-12.4] ng/mL). Univariate analysis
showed that the risk of MACE was greater in the more
elderly patients (OR [95% CI]  1.05 [1.00-1.10]; P  .04),
those with a reduced LVEF (OR [95% CI]  0.96 [0.92-
1.00]; P  .04), or reduced renal function (OR [95% CI] 
0.98 [0.96-1.00]; P  .02), and those with higher baseline
concentrations of myoglobin (OR [95% CI]  1.03 [1.01-
1.05]; P  .002) and PTX3 (OR [95% CI]  1.15 [1.07-1.23];
P  .0002). However, the only variables directly associ-
ated with MACE in a multivariate logistic model that
included the clinical variables and biomarkers were
higher baseline levels of PTX3 (OR [95% CI]  1.13 
Statistical Methods
The changes in biomarker concentrations between
the beginning and end of the rehabilitation period
were tested using the nonparametric Sign test, and a
t test was used to analyze the changes in the 6MWT
results. The differences in baseline biomarker 
concentrations between the patients who underwent
cardiac surgery with or without extracorporeal circu-
lation (on- or off-pump) were tested using the non-
parametric Wilcoxon Mann-Whitney test.
Univariate and multivariable linear regression
models were used to evaluate the associations
between the baseline variables and the 6MWT results
(primary endpoint) on the assumption of the normal
distribution of the 6MWT results being verified by
means of graphical inspection. The clinically relevant
variables of age, gender, body weight, left ventricular
ejection fraction (LVEF), valvular surgery, blood
hemoglobin, leukocyte count, blood glucose, and the
estimated glomerular filtration rate (eGFR, calculated
using the modified MDRD equation) were first evalu-
ated by means of a univariate linear regression
model, and those with a P value  .05 were entered
in a multivariable clinical model. A second multivari-
able linear regression model was built using circulat-
ing concentrations of biomarkers (PTX3, hsCRP, hs-
cTnT, CK, CK-MB, myoglobin, BNP, UACR) following
the same procedure. The clinical variables and circu-
lating biomarkers that were statistically significant in
the univariate analysis were then combined into a
final model.
The significant association between MACE (sec-
ondary endpoint) and the clinical variables (age,
LVEF, eGFR) and circulating biomarkers (myoglobin,
PTX3) upon univariate analyses was tested by means
of multivariable logistic regression. All of the statisti-
cal analyses were made using SAS software (version
9.1: SAS, Inc, Cary, NC).
RESULTS
Table 1 shows the clinical characteristics of the 223
enrolled patients (69.5% male, mean age 67  11
years); 17.6% had a history of previous MI, 9.6% heart
failure, or 39.6% atrial fibrillation; 71.1% were New
York Heart Association (NYHA) class II-IV; 52.7%
were enrolled after valvular surgery and 58.6% after
CABG (combined with valvular surgery in 25 cases).
Mean LVEF at enrolment was 53.6  10.5%.
Upon admission, patients had slightly elevated lev-
els of most of the circulating biomarkers in compari-
son with normal reference values: 100% had PTX3
levels of more than 2.0 ng/mL, 94.1% BNP levels of
more than 100 pg/mL, 94.9% hs-cTnT levels of more
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(beta-estimate [SE]  (2.17 [0.92], P  .02, multivari-
able linear regression model) and LVEF (1.99 [0.74], P
 .009) were significantly associated with 6MWT at
the end of the rehabilitation period, but none of the
assayed circulating biomarkers. On the contrary, base-
line PTX3 concentration was the only variable associ-
ated with MACE in the patients with CABG (OR [95%
CI]  1.14 [1.03-1.27], P  .015, multivariable logistic
regression model).
DISCUSSION
The results of this study confirm that clinical data
such as age, LV ejection fraction, and renal function
are reliable predictors of postrehabilitation functional
recovery and 1-year outcomes in patients who have
undergone cardiac surgery. However, the original
finding is that, considering a panel of hemodynamic,
remodeling, inflammatory and vascular biomarkers,
pentraxin-3 is an independent predictor of short-term
functional recovery after an inpatient cardiac rehabil-
itation program and, together with myoglobinemia, a
predictor of the long-term MACE rate.
Pentraxins are a super family of conserved, multi-
functional acute-phase reactants that play a key role
as effectors and modulators of innate resistance in
animals and humans.18 PTX3 was first identified as an
early gene in vascular endothelial cells and mono-
cytes that is induced in response to proinflammatory
cytokines or stimulation with microbial compo-
nents,19 although it can also be produced by a variety
[1.05-1.22]; P  .0009) and myoglobin (OR [95% CI] 
1.02 [1.004-1.04]; P  .02; Table 5).
Similar analyses were made of the subgroup of 130
patients undergoing rehabilitation after elective CABG
(58.6% of the total study sample). Their mean age was
68  10 years; 18.5% were females; 26.9% had a his-
tory of MI (36.2% atrial fibrillation); 68.0% were pre-
scribed a beta-blocker, 54.3% an angiotensin-convert-
ing enzyme inhibitor or an angiotensin receptor
blocker, and 59.4% a statin. In these patients, only age
20 / Journal of Cardiopulmonary Rehabilitation and Prevention 2012;32:17-24 www.jcrpjournal.com
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Figure 1. Box plots showing the median concentrations (inside the boxes) and interquartile ranges of the biomarkers upon admission
(white boxes) and at the end of the rehabilitation period (shaded boxes); the groups were compared using the Sign test. Abbreviations:
BNP, brain natriuretic peptide; CK, creatine kinase; CK-MB, creatine kinase isoenzyme MB; hsCRP, high-sensitivity C-reactive protein; 
hs-cTnT, high-sensitivity cardiac troponin T; PTX3, pentraxin-3; UACR, urinary albumin-to-creatinine ratio.
T a b l e  1 • Baseline Clinical Characteristics
of the Study Population
Variable n (%) or Mean  SD
N 223 (100%)
Age, y 67  11
Females 68 (30.5%)
Body weight, kg 73  16
History of myocardial infarction 39 (17.6%)
History of heart failure 21 (9.6%)
Coronary artery bypass graft 130 (58.6%)
Valvular surgery 117 (52.7%)
Left ventricular ejection fraction, % 53.6  10.5
6-minute walk test, m 274  97
Laboratory tests
Hemoglobin, g/dL 10.8  1.4
Leukocytes, 103/mm3 9.17  2.70
Serum creatinine, mg/dL 1.09  0.39
eGFR, mL/min/1.73 m2 73  24
Blood glucose, mg/dL 107  33
Abbreviation: eGFR, estimated glomerular filtration rate.
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well as patients undergoing cardiovascular surgery.
The cardioprotective mechanisms evoked during a
program of cardiac rehabilitation include slowing the
progression or reducing the severity of coronary ath-
erosclerosis (improved endothelial function), decreas-
ing chronic inflammation, ensuring moderate losses of
body weight and improved metabolic control (lipid
and insulin sensitivity), ischemic preconditioning of
the myocardium, and favorable hemostatic effects.26-27
To the best of our knowledge, this is the first study
showing a reduction in PTX3 and hs-cTnT levels, and
the UACR in such patients. Very few studies have
monitored the activation of circulating biomarkers in
patients admitted to cardiac rehabilitation, and these
have mainly involved small series of patients with heart
failure and led to conflicting results. A recent study of
95 heart failure patients found that 9 months of aero-
bic training significantly reduced the plasma concen-
trations of BNP and norepinephrine,28 and a study of
44 MI patients enrolled in an exercise-based rehabili-
tation program also found a reduction in BNP levels;5
conversely, a study of physical training involving 
of other cells, including smooth muscle cells and
fibroblasts.20
In addition, neutrophils contain a store of mature
protein in their specific granules and can promptly
release the molecule in response to proinflammatory
signals.21 Pentraxin is also expressed in cardiac tissue
after MI,17-22 and its plasma concentration predicts
cardiovascular morbidity and mortality in patients
with unstable angina,23 MI,24 or heart failure.25
As expected, we found that patients admitted to a
rehabilitation program after cardiac surgery presented
with high concentrations of the biomarkers related to
cardiac stress or injury (brain natriuretic peptide, cardiac
troponin-T, creatine kinase, and myoglobin), generalized
inflammation and vascular injury (C-reactive protein and
pentraxin-3), and early renal glomerular dysfunction
(albumin urinary excretion), but the marked decrease in
biomarker levels during rehabilitation supports the glob-
al effectiveness of even short-term programs.
Neurohormonal activation has been documented in
most candidates for cardiac rehabilitation, be they
patients with a recent MI or chronic heart failure, as
www.jcrpjournal.com Biomarkers and CR / 21
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T a b l e  2 • Clinical Determinants of 6MWT at the End of the Rehabilitation Period
Univariate Model Multivariable Model
Variable Estimate (SE) t Value P Value Estimate (SE) t Value P Value
Age 3.54 (0.55) 6.41 .0001 2.71 (0.62) 4.36 .0001
Gender 14.09 (14.60) 0.96 .34
Body weight 0.11 (0.41) 0.27 .78
LV ejection fraction 2.47 (0.61) 4.08 .0001 2.26 (0.55) 4.10 .0001
Valvular surgery 18.48 (13.12) 1.41 .16
Hemoglobin 2.18 (4.89) 0.45 .66
White blood cell count 0.001 (0.003) 0.58 .57
Blood glucose 0.07 (0.20) 0.36 .72
eGFR 1.47 (0.26) 5.65 .0001 0.68 (0.29) 2.35 .02
Abbreviations: eGFR, estimated glomerular filtration rate; LV, left ventricular; 6MWT, 6 minute walk test.
T a b l e  3 • Biomarkers Associated With 6MWT at the End of the Rehabilitation Period
Univariate Model Multivariable Model
Biomarker Estimate (SE) t P Value Estimate (SE) t P Value
hs-CRP 1.04 (2.63) 0.40 .69
PTX3 3.49 (1.16) 3.02 .003 3.02 (1.18) 2.55 .01
BNP 0.032 (0.016) 2.04 .043 0.024 (0.016) 1.52 .13
hs-cTnT 0.011 (0.051) 0.22 .83
CK 0.38 (0.23) 1.64 .10
CK-MB 1.19 (2.44) 0.49 .63
Myoglobin 0.70 (0.35) 2.00 .047 0.51 (0.35) 1.44 .15
UACR 0.0091 (0.0385) 0.24 .81
Abbreviations: BNP, brain natriuretic peptide; CK, creatine kinase; CK-MB, creatine kinase isoenzyme MB; hsCRP, high-sensitivity C-reactive protein; 
hs-cTnT, high-sensitivity cardiac troponin T; PTX3, pentraxin-3; 6MWT, 6 minute walk test; UACR, urinary albumin-to-creatinine ratio.
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patients with acute MI or undergoing CABG random-
ized to an expanded cardiac rehabilitation program or
usual rehabilitation.31
Even fewer studies have investigated the useful-
ness of cardiac biomarkers as early predictors of out-
come, although it was found that initial plasma BNP
levels and an anterior MI predicted left ventricular
remodeling in 72 patients enrolled in a 12-week pro-
gram of cardiac rehabilitation.32 We found that PTX3,
43 patients with heart failure found no reduction in
plasma natriuretic peptide (ANP and BNP) concentra-
tions.29 Another study of 277 patients with coronary
heart disease found that completing a 3-month formal
program of cardiac rehabilitation and exercise train-
ing significantly reduced the plasma levels of CRP (a
nonspecific marker of inflammation), regardless of
the use of statins or weight loss.30 Circulating CRP and
fibrinogen levels were similarly reduced in 224
22 / Journal of Cardiopulmonary Rehabilitation and Prevention 2012;32:17-24 www.jcrpjournal.com
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T a b l e  4 • Clinical and Biohumoral Determinants of 6MWT at the End of
the Rehabilitation Perioda
Variable Estimate (SE) t P Value
Age 2.53 (0.63) 4.00 .0001
LV ejection fraction 2.12 (0.58) 3.65 .0003
eGFR 0.67 (0.31) 2.15 .03
PTX3 1.94 (1.08) 1.80 .07
BNP 0.0013 (0.0144) 0.09 .93
Myoglobin 0.089 (0.331) 0.27 .79
aMultivariable model.
Abbreviations: 6MWT, 6-minute walk test; BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate;
LV, left ventricular; PTX3, pentraxin-3.
T a b l e  5 • Clinical and Biohumoral Determinants of Major Adverse Cardiovascular Events (MACE)
at the End of the 1-Year Followup Period
Univariate Logistic Model Multivariate Logistic Model
Variable OR 95% CI P Value OR 95% CI P Value
Clinical variables
Age 1.049 1.002-1.098 .042 1.023 0.968-1.080 .417
Gender 1.184 0.465-3.013 .724
Body weight, kg 0.976 0.945-1.007 .125
LV ejection fraction 0.960 0.924-0.998 .041 0.960 0.922-1.000 .050
Valvular surgery 1.117 0.475-2.627 .800
Hemoglobin 0.734 0.510-1.056 .096
White blood cell count 1.000 1000-1.000 .948
Blood glucose 0.997 0.983-1.012 .701
eGFR 0.976 0.957-0.996 .020 0.980 0.957-1.004 .102
Biohumoral markers
Hs-CRP 1.022 0.843-1.241 .822
BNP 1.000 1.000-1.000 .207
CK 1.004 0.992-1.017 .510
CK-MB 1.093 0.998-1.197 .056
Myoglobin 1.029 1.011-1.047 .002 1.023 1.004-1.043 .018
hs-cTnT 1.002 0.999-1.004 .223
PTX3 1.148 1.067-1.234 .0002 1.132 1.052-1.218 .0009
Microalbuminuria 1.001 1.000-1.003 .1082
Clinical variables and biohumoral markers
LV ejection fraction 0.966 0.923-1.011 .139
Myoglobin 1.02 1.004-1.04 .016
PTX3 1.13 1.05-1.22 .0009
Abbreviations: BNP, brain natriuretic peptide; CK, creatine kinase; CK-MB, creatine kinase isoenzyme MB; eGFR, estimated glomerular filtration rate; hsCRP,
high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; LV, left ventricular; PTX3, pentraxin-3.
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cannot be completely ruled out. Finally, the study
was not designed to evaluate the cost-effectiveness of
using circulating biomarkers for risk stratification in
cardiac rehabilitation. However, in the absence of
conclusive data in this area, it may be considered
reassuring to point out that the inexpensive measure-
ment of a single biomarker of vascular inflammation
and injury helped clinicians to predict short-term
functional recovery and long-term cardiovascular
events in our study population. The strength of the
study lies in its multicenter prospective design and
the fact that it investigated novel cardiac biomarkers
in a relatively large number of patients.
CONCLUSIONS
The results of the study confirm that clinical and
instrumental parameters (age, LV ejection fraction,
eGFR) are reliable predictors of functional recovery in
cardiac surgical patients admitted to a program of car-
diac rehabilitation. In addition to robust clinical vari-
ables, PTX3 (a pleiotropic marker of vascular inflam-
mation and cardiovascular system damage) is an
independent predictor of short-term functional recov-
ery, and the baseline concentration of PTX3 was the
only variable associated with the 1-year MACE rate in
our CABG patients. Given the widespread interest in
biomarkers in cardiology and the paucity of evidence
in the field of rehabilitation, there is a clear need for
well-designed clinical studies aimed at improving our
understanding of their role in cardiac rehabilitation.
Whether knowledge of the circulating concentrations
of PTX3 may help to stratify surgical patients referred
for rehabilitation and predict their outcome needs to
be confirmed.
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between plasma PTX3 levels and rehabilitative out-
come in cardiac surgery patients. In addition, it has
recently been found that pentraxin predicts higher
hospital mortality in patients with severe traumatic
brain injury,33 that it is a useful marker of severe dis-
ease in febrile patients attending an emergency
department,34 and that it predicts of cognitive impair-
ment in elderly hypertensive patients.35
In the absence of previous evidence concerning
the role of PTX3 in exercise training or rehabilitation,
this may simply be because the complexity and inte-
gration of the physiological mechanisms involved in
functional recovery after cardiac surgery is better
reflected by a molecule that is largely produced by
activated endothelial cells. Once again, it is worth
noting that the circulating biomarkers that were more
greatly reduced after rehabilitation (hsCRP, hs-cTnT,
and UACR) did not seem to be independent predic-
tors of the 6MWT results.
LIMITATIONS
There are some limitations to this study. First of all,
all of the postcardiac surgery patients were inpatients,
and it is not possible to extrapolate the evolution and
prognostic value of circulating biomarkers in subjects
not admitted to a rehabilitation unit. Moreover, for
ethical reasons, the study was designed as an obser-
vational study. Secondly, as the number of
patients/events is limited, the risk of model overfitting
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